DANA-FARBER CANCER INSTITUTE

Acalabrutinib plus venetoclax, with or without obinutuzumab, improved PFS over standard-of-care chemoimmunotherapy in treatment-naive CLL patients, reducing progression risk by 35% and 58%, respectively.

Dana-Farber researchers presented promising results at ASH for systemic mastocytosis, including bezuclastinib's efficacy and a mathematical model distinguishing disease forms.

CALQUENCE plus venetoclax with obinutuzumab reduced the risk of disease progression or death by 58% versus standard-of-care chemoimmunotherapy in previously untreated adult patients with chronic lymphocytic leukemia (CLL). CALQUENCE plus venetoclax demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to standard-of-care chemoimmunotherapy.

AMPLIFY trial interim analysis shows acalabrutinib plus venetoclax with or without obinutuzumab significantly improves progression-free survival (PFS) in untreated chronic lymphocytic leukemia (CLL) compared to standard-of-care chemoimmunotherapy, with median PFS not reached in the acalabrutinib plus venetoclax arms and 47.6 months in the SOC arm. The combination reduced the risk of disease progression or death by 35% for the doublet and 58% for the triplet regimen.

Acalabrutinib plus venetoclax, with or without obinutuzumab, significantly improved progression-free survival (PFS) in treatment-naive chronic lymphocytic leukemia (CLL) patients compared to standard-of-care chemoimmunotherapy, according to the AMPLIFY trial. The 36-month PFS rates were 83.1% and 76.5% with the combinations, versus 66.5% with SOC. The triplet regimen showed better PFS, especially for patients with unmutated IGHV, and higher undetectable minimal residual disease rates.

CALQUENCE plus venetoclax with obinutuzumab reduced the risk of disease progression or death by 58% versus standard of care in previously untreated adult patients with chronic lymphocytic leukemia (CLL). CALQUENCE plus venetoclax demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to standard-of-care chemoimmunotherapy.

Cogent Biosciences reports positive data from Phase 2 APEX trial on bezuclastinib for advanced systemic mastocytosis at ASH 2024, showing 52% ORR per mIWG criteria and 88% ORR per PPR criteria, with median time to response of 2.2 months. Top-line data from APEX Part 2 expected mid-2025.

Acalabrutinib plus venetoclax, with or without obinutuzumab, shows deep and durable responses in CLL patients, with AV and AVO regimens achieving 76.5% and 83.1% 36-month PFS, respectively, compared to 66.5% for standard chemoimmunotherapy. AVO also demonstrated a 95% rate of undetectable MRD.

CALQUENCE plus venetoclax reduced CLL progression/death risk by 35% vs. chemoimmunotherapy at 41 months follow-up. CALQUENCE plus venetoclax with obinutuzumab showed a 58% reduction. Median PFS not reached for experimental arms vs. 47.6 months for chemoimmunotherapy. OS trend favorable for CALQUENCE plus venetoclax (HR 0.33; p<0.0001).

Calquence plus venetoclax showed superior PFS in previously untreated CLL, reducing progression risk by 58% vs. standard care in AMPLIFY Phase III trial. This all-oral fixed-duration regimen could offer new treatment flexibility for patients.